Bolt Biotherapeutics, Inc. (BOLT) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-02-04

Key Insights

The reporting person, Sarah Nemec, acquired 125 shares of common stock of Bolt Biotherapeutics, Inc. through an employee stock purchase plan transaction on December 5, 2025.
Nemec also received an 8,000 share stock option grant on January 28, 2026, which vests over 36 months of continuous service.
These transactions suggest Nemec, a senior finance executive, has confidence in the company and is increasing her ownership stake.

Want the newest filings?

This analysis covers the filing from 2026-02-04. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-02-04

The reporting person, Grant Yonehiro, was granted 10,000 stock options as the Chief Operating Officer of Bolt Biotherapeutics, Inc. (BOLT), with a strike price of $6.71 and a 10-year expiration date.
The stock options will vest over a 3-year period, with 1/36th of the shares vesting each month, indicating a long-term commitment from the executive to the company.
This filing indicates insider ownership and alignment between management and shareholders, which can be a positive signal for investors.

Filed: 2026-02-04

The reporting person, William P. Quinn, purchased 125 shares of common stock in the company, indicating potential confidence in the company's outlook.
Quinn, who is the President, CEO and CFO, was granted 20,000 stock options with a 10-year expiration, aligning his incentives with long-term shareholder value creation.
The insider trading activity suggests that management is optimistic about the company's future prospects and is willing to invest in the stock.

Other reports for Bolt Biotherapeutics, Inc.

Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.